157 related articles for article (PubMed ID: 18528893)
1. The utility of Pax-2 as an immunohistochemical marker for renal cell carcinoma in cytopathology.
Gokden N; Kemp SA; Gokden M
Diagn Cytopathol; 2008 Jul; 36(7):473-7. PubMed ID: 18528893
[TBL] [Abstract][Full Text] [Related]
2. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker.
Gokden N; Gokden M; Phan DC; McKenney JK
Am J Surg Pathol; 2008 Oct; 32(10):1462-7. PubMed ID: 18685487
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry for the detection of renal cell carcinoma in effusion cytology.
Chute DJ; Kong CS; Stelow EB
Diagn Cytopathol; 2011 Feb; 39(2):118-23. PubMed ID: 21254459
[TBL] [Abstract][Full Text] [Related]
4. The utility of PAX-2 and renal cell carcinoma marker immunohistochemistry in distinguishing papillary renal cell carcinoma from nonrenal cell neoplasms with papillary features.
Sharma SG; Gokden M; McKenney JK; Phan DC; Cox RM; Kelly T; Gokden N
Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):494-8. PubMed ID: 21102195
[TBL] [Abstract][Full Text] [Related]
5. Pax-2 expression in adult renal tumors.
Daniel L; Lechevallier E; Giorgi R; Sichez H; Zattara-Cannoni H; Figarella-Branger D; Coulange C
Hum Pathol; 2001 Mar; 32(3):282-7. PubMed ID: 11274636
[TBL] [Abstract][Full Text] [Related]
6. Useful immunohistochemical markers in differentiating hemangioblastoma versus metastatic renal cell carcinoma.
Rivera AL; Takei H; Zhai J; Shen SS; Ro JY; Powell SZ
Neuropathology; 2010 Dec; 30(6):580-5. PubMed ID: 20374497
[TBL] [Abstract][Full Text] [Related]
7. Image analysis of proliferating cell nuclear antigen expression and immunohistochemical profiles in renal cell carcinoma associated with acquired cystic kidney disease: comparison with classic renal cell carcinoma.
Khurana KK; Truong LD; Verani RR
Mod Pathol; 1998 Apr; 11(4):339-46. PubMed ID: 9578084
[TBL] [Abstract][Full Text] [Related]
8. PAX2 expression in Wilms tumors and other childhood neoplasms.
Davis JL; Matsumura L; Weeks DA; Troxell ML
Am J Surg Pathol; 2011 Aug; 35(8):1186-94. PubMed ID: 21730820
[TBL] [Abstract][Full Text] [Related]
9. Immunophenotypic comparison of salivary gland oncocytoma and metastatic renal cell carcinoma.
Ozolek JA; Bastacky SI; Myers EN; Hunt JL
Laryngoscope; 2005 Jun; 115(6):1097-100. PubMed ID: 15933529
[TBL] [Abstract][Full Text] [Related]
10. Anti-alpha-inhibin: marker of choice for the consistent distinction between adrenocortical carcinoma and renal cell carcinoma in fine-needle aspiration.
Fetsch PA; Powers CN; Zakowski MF; Abati A
Cancer; 1999 Jun; 87(3):168-72. PubMed ID: 10385449
[TBL] [Abstract][Full Text] [Related]
11. CD70: a new tumor specific biomarker for renal cell carcinoma.
Junker K; Hindermann W; von Eggeling F; Diegmann J; Haessler K; Schubert J
J Urol; 2005 Jun; 173(6):2150-3. PubMed ID: 15879877
[TBL] [Abstract][Full Text] [Related]
12. PAX2 and PAX8 expression in primary and metastatic renal tumors: a comprehensive comparison.
Ozcan A; de la Roza G; Ro JY; Shen SS; Truong LD
Arch Pathol Lab Med; 2012 Dec; 136(12):1541-51. PubMed ID: 23194047
[TBL] [Abstract][Full Text] [Related]
13. A panel of immunohistochemical stains assists in the distinction between ovarian and renal clear cell carcinoma.
Cameron RI; Ashe P; O'Rourke DM; Foster H; McCluggage WG
Int J Gynecol Pathol; 2003 Jul; 22(3):272-6. PubMed ID: 12819395
[TBL] [Abstract][Full Text] [Related]
14. D2-40 is a sensitive and specific marker in differentiating primary adrenal cortical tumours from both metastatic clear cell renal cell carcinoma and phaeochromocytoma.
Browning L; Bailey D; Parker A
J Clin Pathol; 2008 Mar; 61(3):293-6. PubMed ID: 17660332
[TBL] [Abstract][Full Text] [Related]
15. The distinction of clear cell carcinoma of the female genital tract, clear cell renal cell carcinoma, and translocation-associated renal cell carcinoma: an immunohistochemical study using tissue microarray.
He H; Zhou GX; Zhou M; Chen L
Int J Gynecol Pathol; 2011 Sep; 30(5):425-30. PubMed ID: 21804394
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis for cytokeratin 7, KIT, and PAX2: value in the differential diagnosis of chromophobe cell carcinoma.
Memeo L; Jhang J; Assaad AM; McKiernan JM; Murty VV; Hibshoosh H; Tong GX; Mansukhani MM
Am J Clin Pathol; 2007 Feb; 127(2):225-9. PubMed ID: 17210525
[TBL] [Abstract][Full Text] [Related]
17. Comparison of PAX-2, RCC antigen, and antiphosphorylated H2AX antibody (gamma-H2AX) in diagnosing metastatic renal cell carcinoma by fine-needle aspiration.
Wasco MJ; Pu RT
Diagn Cytopathol; 2008 Aug; 36(8):568-73. PubMed ID: 18618717
[TBL] [Abstract][Full Text] [Related]
18. PAX-2 in the diagnosis of primary renal tumors: immunohistochemical comparison with renal cell carcinoma marker antigen and kidney-specific cadherin.
Ozcan A; Zhai J; Hamilton C; Shen SS; Ro JY; Krishnan B; Truong LD
Am J Clin Pathol; 2009 Mar; 131(3):393-404. PubMed ID: 19228645
[TBL] [Abstract][Full Text] [Related]
19. PAX 2: a novel Müllerian marker for serous papillary carcinomas to differentiate from micropapillary breast carcinoma.
Chivukula M; Dabbs DJ; O'Connor S; Bhargava R
Int J Gynecol Pathol; 2009 Nov; 28(6):570-8. PubMed ID: 19851209
[TBL] [Abstract][Full Text] [Related]
20. PAX-2 is a helpful marker for diagnosing metastatic renal cell carcinoma: comparison with the renal cell carcinoma marker antigen and kidney-specific cadherin.
Ozcan A; Zhai Q; Javed R; Shen SS; Coffey D; Krishnan B; Truong LD
Arch Pathol Lab Med; 2010 Aug; 134(8):1121-9. PubMed ID: 20670131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
